rostate canc
er) is a Phase I/IIa study for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (mCRPC), which will be conducted in the U.S. (NCT04868604)
[1]. It is a theranostic multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients. The trial employs diagnostic Positron Emission Tomography imaging with
64Cu-SAR-bisPSMA for selection of patients suitable for therapy cycles with
67Cu-SAR-bis-PSMA.
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of death worldwide
[2]. The American Cancer Society estimates in 2021 there will be 248,530 new cases of prostate cancer in the U.S. and around 34,130 deaths from the disease